Short Interest in Avenue Therapeutics, Inc. (NASDAQ:ATXI) Expands By 7.4%

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the target of a large growth in short interest in May. As of May 31st, there was short interest totalling 49,500 shares, a growth of 7.4% from the May 15th total of 46,100 shares. Based on an average daily volume of 61,000 shares, the short-interest ratio is currently 0.8 days. Approximately 6.0% of the shares of the stock are short sold.

Avenue Therapeutics Trading Down 6.5 %

Shares of Avenue Therapeutics stock traded down $0.24 on Monday, reaching $3.47. The stock had a trading volume of 23,995 shares, compared to its average volume of 70,418. Avenue Therapeutics has a 1 year low of $3.25 and a 1 year high of $93.75. The company has a market cap of $3.27 million, a P/E ratio of -0.44 and a beta of -0.10. The business’s 50 day moving average is $5.64 and its two-hundred day moving average is $9.63.

Avenue Therapeutics (NASDAQ:ATXI) last announced its earnings results on Wednesday, May 15th. The company reported ($15.40) earnings per share (EPS) for the quarter.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.